Dupixent may help some people with inadequately controlled COPD who have a type of lung inflammation that worsens symptoms.

The FDA has approved Dupixent as an add-on maintenance treatment for adults with poorly controlled COPD and high counts of ...

Ohtuvayre (ensifentrine) is a first-in-class selective dual inhibitor of the enzymes phosphodiesterase three and phosphodiesterase 4 (“PDE3 and PDE4”) that combines bronchodilator and non-steroidal ...

Chronic obstructive lung disease, also known as chronic obstructive pulmonary disease (COPD), is a general term for a group ...

Changes in people’s voices recoded on a smartphone can signal a serious flare up in symptoms of chronic obstructive pulmonary ...

The National Medical Products Administration approved Dupixent as an add-on maintenance treatment for adults with ...

China NMPA approves Sanofi & Regeneron’s Dupixent as an add-on maintenance treatment for adults with uncontrolled COPD: Paris Monday, September 30, 2024, 11:00 Hrs [IST] The Nat ...

Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing ...

Dupixent is the first biologic medicine approved in the U.S. for the common lung condition, though competitors from GSK, AstraZeneca and Roche could follow.

Dupixent, commonly used to treat eczema and asthma, was cleared for a subset of patients with chronic obstructive pulmonary disease.

N-acetylcysteine (NAC) nebulizer therapy is effective and safe as a short-term (12-week) treatment for reducing phlegm in chronic obstructive pulmonary disease (COPD), according to study findings ...

With asthma and chronic obstructive pulmonary disease (COPD) on the rise, worsened by air pollution, tobacco use, and ...